Lineage-specific regulation of the murine RAG-2 promoter: GATA-3 in T cells and Pax-5 in B cells

Hiroyuki Kishi, Xing-Cheng Wei, Zhe-Xiong Jin, Yoshiyuki Fujishiro, Takuya Nagata, Tadashi Matsuda, and Atsushi Muraguchi

Recombination activating gene-1 (RAG-1) and RAG-2 are expressed in lymphoid cells undergoing the antigen receptor gene rearrangement. A study of the regulation of the mouse RAG-2 promoter showed that the lymphocyte-specific promoter activity is conferred 80 nucleotide (nt) upstream of RAG-2. Using an electrophoretic mobility shift assay, it was shown that a B-cell–specific transcription protein, Pax-5, and a T-cell–specific transcription protein, GATA-3, bind to the −80 to −17 nt region in B cells and T cells, respectively. Mutation of the RAG-2 promoter for Pax-5– and GATA-3–binding sites results in the reduction of promoter activity in B cells and T cells. These results indicate that distinct DNA binding proteins, Pax-5 and GATA-3, may regulate the murine RAG-2 promoter in B and T lineage cells, respectively. (Blood. 2000;95:3845-3852)

Introduction

Recombination activating gene-1 (RAG-1)1 and RAG-2 are the essential and tissue-specific components of the V(D)J recombination.1,2 It has been demonstrated that these genes are sufficient for the recognition and initial cleavage of DNA containing recombination signal sequences.3,4 Disruption of either RAG-1 or RAG-2 in the germline of a mouse completely prevents the rearrangement of immunoglobulin (Ig) and T cell receptor (TCR) genes and blocked the development of mature B and T lymphocytes.3,8 It has also been shown that the mutation of human RAG-1 or RAG-2 caused severe combined immunodeficiency without B lymphocytes5 and Omenn syndrome with a few antigen repertoires of lymphocytes.10

RAG-1 and RAG-2 expressions are lymphoid-specific and are regulated developmentally.11,12 RAG-1 and RAG-2 are expressed in pro-B cells or pro-T cells in a concordant manner when rearrangement of the IgH or TCRβ chain gene occurs. Secondary expression of RAG-1 and RAG-2 occurs when the IgL or TCRα chain loci undergo VJ rearrangement to produce mature B or T cells. Recently it has been demonstrated that antigen stimulation induces reexpression of RAG-1 and RAG-2 in mature lymphocytes in peripheral lymphoid organs,13,14 which indicates that RAG-1 and RAG-2 play a role in editing the lymphocyte repertoire in the periphery.15

We and others have been studying the transcriptional regulation of the RAG gene.17,18 It has been shown that the 5′ flanking region of the human RAG-1 gene functions as a minimal promoter, but it does not confer lymphocyte-specific expression of RAG-1. Concerning the lymphocyte-specificity and differentiation stage–specificity of the RAG-1 expression, it has been demonstrated that alteration of the chromatin structure detected by deoxyribonuclease I (DNase I) hypersensitivity takes place in accordance with the RAG-1 expression.19,20 In this report we describe the lymphocyte-specific promoter activity of the mouse RAG-2 5′ flanking region and demonstrate that distinct lymphoid-specific transcriptional factors are required for activation of the murine RAG-2 promoter in B and T lymphocytes.

Materials and methods

Isolation of mouse RAG-2 genomic clones

Mouse RAG-2 genomic clones were isolated from a λ FIX II library (Stratagene, La Jolla, CA) and screened by using a radio-labeled full-length mouse RAG-2 complementary DNA (cDNA) as described previously.17 Several clones were isolated, and 2 of them (mRAG-2-4 and mRAG-2-6) were analyzed by restriction enzyme mapping and DNA sequencing (Dye Terminator Cycle Sequencing FS Ready Reaction Kit; Perkin-Elmer, Foster City, CA).

5′ rapid amplification of cDNA ends (RACE)

5′ RACE was performed (5′ RACE System; Life Technologies, Gaithersburg, MD) according to the manufacturer’s instruction. Briefly, poly-A+ RNA was prepared from thymocytes and reverse transcribed with Superscript II reverse transcriptase (RT) for 50 minutes at 42°C with 2.5 pmol of gene-specific primer 1 (GSP1) located at 392-412 base pair (bp) of mouse RAG-2 cDNA1 (5′-GAG TCT A TG CTG CCT TTG TA-3′). After ribonuclease (RNase) H digestion, cDNA was purified with GLASSMAX spin cartridge and tailed with deoxycytidine 5′-triphosphate (dCTP) using terminal deoxynucleotidyltransferase. The cDNA was subsequently amplified in a polymerase chain reaction (PCR) using an anchor primer and GSP2, which is located at 165-184 bp of mouse RAG-2 cDNA1 (5′-CAU CAU CAU TGA CCC ACT GTT ACC ATC TG-3′). PCR conditions included 1 cycle of 2 minutes at 94°C followed by 35 cycles of 0.5 minutes at 94°C, 0.5 minutes at 55°C, 2 minutes at 72°C, and finally an extension for 7 minutes at 72°C. The amplified products were subcloned into pT7Blue-T vector (Novagen, Madison, WI) and subjected to DNA sequencing analysis as described above.

Cell lines and cell culture

The following cell lines were used for transfection or preparation of nuclear extracts: 18.8.1 (pre-B cell, RAG-2−),21 BAL17 (B cell, RAG-2−), and WEHI279 (B cell, RAG-2−)22 (gift of K Sakaguchi, Kumamoto University, Kumamoto, Japan); WEHI231 (B cell, RAG-2−)23 and M1 (myeloid, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, 930-0194 Japan; e-mail: gucci@ms.toyama-mpu.ac.jp.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology

From the Department of Immunology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.

Submitted October 8, 1999; accepted February 11, 2000.

Supported by a grant-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan (11470169), Tokyo, Japan.

Reprints: Atsushi Muraguchi, Department of Immunology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, 930-0194 Japan; e-mail: gucci@ms.toyama-mpu.ac.jp.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology
RAG-2-γ (gift of Dr H. Kikutani, Osaka University, Osaka, Japan); LSBl-1 (T cell, RAG-2-γ), EL4 (T cell, RAG-2-γ), 110T (T cell, RAG-2-γ), WEHI3 (myeloid, RAG-2-γ), L (fibroblast, RAG-2-γ); and NIH3T3 (fibroblast, RAG-2-γ). Expression of RAG-2 mRNA in the cell lines was examined by RT-PCR as described by Chun et al.21 All cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 50 µg/mL 2-mercaptoethanol, 100 U/mL penicillin, and 0.1 µg/mL streptomycin at 37°C in 5% carbon dioxide (CO2).

**Construction of plasmids**

RAG-2 promoter fragments were generated by PCR using the cloned genomic DNA as a template; the oligonucleotide 1 as a common primer; and the oligonucleotides 2 (−639 to +147 nt genomic DNA fragment [−639/+147]), 3 (−430/+147), 4 (−86/+147), and 5 (−41/+147) as 5′ primers. Amplified fragments were cloned into the pT7Blue-T vector. The fragments were then cut out by digesting with NcoI and Sall restriction enzymes and reinserted into the NcoI and XhoI restriction enzyme sites of the PicaGene basic vector 2 or enhancer vector 2 (Nippon Gene, Tokyo, Japan). To prepare the luciferase construct with either the −251/+147 or +44/+147 fragment, the luciferase construct with the −430/+147 fragment was digested with either restriction enzymes NdeI and HindIII or NdeI and PstI and then blunt-end ligated. Mouse βTCR 3′ enhancer22 was cloned into the SpeI and KpnI restriction enzyme sites of the luciferase constructs in the PicaGene basic vector 2.

For preparation of the −86/+147 fragment with a mutation for a Pax-5 binding site (M2 mutation), the −86/+17 fragment with the M2 mutation was prepared by PCR using the cloned genomic DNA as a template and primers 6 and 7, and the −33/+147 fragment with the M2 mutation was prepared using primers 1 and 8. The −86/+147 fragment with the M2 mutation was amplified using both the −86/+17 fragment with the M2 mutation and the −33/+147 fragment with the M2 mutation as templates and primers 1 and 4. The −86/+147 fragment with mutation for the GA TA binding site was prepared by PCR using the cloned genomic DNA as a template and primers 1 and 9.

**Transfection and luciferase assay**

For transfection of luciferase constructs into cells other than fibroblasts, the DEAE dextran method was used. Briefly, 5 × 10⁶ cells were incubated in 1 mL 0.5 mg/mL diethylaminoethyl (DEAE) dextran (Pharmacia, Uppsala, Sweden) in Tris-buffered (tris(hydroxymethyl)aminomethane–buffered) saline containing 5 µg luciferase reporter gene and 5 µg psRac-lac-Z gene17 at 37°C for 20 minutes at room temperature. Cells were washed and incubated in RPMI 1640 medium containing 10% FCS and 100 µg/mL chloroquine (Sigma Chemical, St Louis, MO) for 60 minutes at 37°C. Cells were then spun down and reincubated in RPMI 1640 containing 10% FCS at 37°C. For transfection into fibroblasts, the calcium phosphate method was used. Briefly, DNA precipitation was prepared by adding 456 µL DNA solution containing 15 µg luciferase reporter gene, 15 µg pSPlac-Z gene, and 0.25 mol/L calcium dichloride (CaCl₂) into 456 µL 0.05 mol/L HEPES (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.1), 0.28 mol/L sodium chloride (NaCl), 0.17 mol/L sodium dihydrogenphosphate (Na₂HPO₄), and 0.7 mol/L sodium hydrogenphosphate (NaH₂PO₄). After precipitation at room temperature with the DNA precipitate was added evenly over a 10-cm plate of cells in Dulbecco’s Modified Eagle Medium (D-MEM) containing 10% FCS. Cells were harvested 24-24 hours after transfection, and luciferase activity and β-galactosidase activity was measured as described previously.17 The luciferase constructs used for the luciferase reporter gene assay contained either the βTCR enhancer or SV40 enhancer to augment the transcriptional activity. This was done because a genomic DNA fragment spanning from the −1.1 kb to +147 nt or its truncated fragments linked upstream of the luciferase gene showed undetectable luciferase activity in the absence of an enhancer region in any cell lines including the RAG-2-expressing lymphocyte cell lines. The constructs with the βTCR enhancer were introduced into RAG-2-expressing (LSBl-1, 18.8.1, or BALB/17) cell lines or RAG-2–nonexpressing (EL4 or 110TC) lymphoid cell lines. The constructs with the SV40 enhancer were introduced into nonlymphoid cell lines (L and NIH3T3) as well as 18.8.1, a pre-B cell line.

**Electrophoretic mobility shift assay**

Electrophoretic mobility shift assay (EMSA) was performed according to the method described by Schreiber et al.23 The following fragments were used as a probe DNA: −80/+17 fragment, −85/+56 fragment, or the fragment containing the tandemly repeated GATA binding sequence. The probe DNA was labeled with α32P-dATP by filling with the Klenow fragment. Nuclear extracts (2 µL) were incubated with the 32P-labeled probe DNA at room temperature for 20 minutes in 15 µL reaction mixture containing 4% Ficol 400 (Pharmacia), 20 mmol/L HEPES (pH 7.9), 50 mmol/L potassium chloride (KCl), 1 mmol/L ethylenediamine tetraacetic acid (EDTA), 1 mmol/L dithiothreitol (DTT), 0.25 mg/mL bovine serum albumin (BSA), and 1-µg poly(dI-dC) (Pharmacia). After incubation samples were loaded onto a 4% polyacrylamide gel, which was prerun for 1 hour at 4°C (100 V) in Tris-glycine buffer and electrophoresed at 4°C (100 V) for 2-3 hours. The gels were dried and exposed to X-ray film (Fuji Film, Tokyo, Japan). For preparation of nuclear extracts containing recombinant GATA-3, an expression vector for mouse GATA-3 cDNA (gift of Dr M. Yamamoto, Tsukuba University, Tsukuba, Japan) was transfected into 293T cells by a calcium phosphate method, and nuclear extracts were prepared 24 hours after transfection.

Where indicated, competitor DNA or antibodies to transcription factors (Santa Cruz Biotechnology, Santa Cruz, CA) were added to the binding reaction. Competitor DNA was prepared by PCR using the following primer pairs (fragments): 6/10 (−80/+17), 6/11 (−80/+42), 6/12 (−80/+30), 13/12 (−65/+30), 13/10 (−65/+17), or 14/10 (−51/+17). For preparation of the mutated −80/+17 fragment, the following primer pairs (fragments) were used: 6/15 (−80/+17M1), 6/7 (−80/+17M2), 6/16 (−80/+17M3), or 6/17 (−80/+17M4). Consensus binding sequences were determined by DNA sequencing.

**Oligonucleotides**

The following oligonucleotides were used in this study: 1, 5′-GGGGTACCATGGCGACGGGCTGCTTAC-3′; 2, 5′-CCATCATCAAGCTTTGTTGGAAG-3′; 3, 5′-CCCTGATTACACACAGATGCA-3′; 4, 5′-TCCCTGATCCCTACCAC-3′; 5, 5′-AGTCACAGTCTATGTTACCTCC-3′; 6, 5′-GCTCTAGATCCTCCCTCACCACATCAGG-3′; 7, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 8, 5′-TCTCTTCTGCTCCCTCACCACATCAGG-3′; 9, 5′-TTCTCTTCTGCTCCCTCACCACATCAGG-3′; 10, 5′-GCTCTAGATACGGATAGGTAATATG-3′; 11, 5′-GGCCTTCCCCTCCCTGCTAACCAC-3′; 12, 5′-TGGTACTGATACGGATAGGTAATATG-3′; 13, 5′-ACAGGGTGTCAGGGGTAGGGGGAA-3′; 14, 5′-AGGGGAGGAGGGTGACAGT-3′; 15, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 16, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 17, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 18, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 19, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 20, 5′-TGGTACTGATACGGATAGGTAATATG-3′; 21, 5′-ACACTGTCGGAACTGTCGCTGCAC-3′; 22, 5′-TGGTACTGATACGGATAGGTAATATG-3′; 23, 5′-AGGGGAGGAGGGTGACAGT-3′; 24, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 25, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 26, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 27, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 28, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 29, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′; 30, 5′-TACACTGTCGGAACTGTCGCTGCAC-3′.

**Results**

**Isolation of mouse RAG-2 genomic DNA clones and characterization of its 5′ flanking region**

Mouse genomic clones mRAG-2-4 and mRAG-2-6, which contain the total DNA region of the published mouse RAG-2 cDNA,1 were isolated by screening a mouse genomic DNA library. Restriction
enzyme mapping. Southern blot hybridization, DNA sequencing analysis of these clones, and Southern blot hybridization analysis of mouse genomic DNA revealed that the mouse RAG-2 genome consists of 3 exons (data not shown).

To determine the transcription start site of the mouse RAG-2 genome, 5' RACE was performed using mouse thymocyte poly-A+ RNA. We sequenced 16 clones that contain anticipated restriction enzyme sites. As shown in Figure 1, transcription initiated primarily from 2 adjacent nucleotides. No TATA box is present at the 5' upstream region of the mouse RAG-2 genome. At the major transcription initiation site, there is a sequence (CTCAGTCG) similar to an initiator sequence (CTCANTCT), which directs the initiation site of transcription. Comparison of nucleotide sequences around the transcription initiation site of the mouse and the human RAG-2 genome (Figure 1B) revealed that the promoter region is conserved between mice and humans. The reported transcription initiation site of the human RAG-2 genome is about 30 bp downstream from that of the mouse RAG-2 genome.

Lymphoid-specific promoter activity in mouse RAG-2 5' flanking region

The promoter activity of the 5' flanking region of the mouse RAG-2 gene was examined by a transient expression assay using luciferase reporter gene constructs (Figures 2 and 3). Because the luciferase activity of the mouse RAG-2 promoter constructs was too weak to be detected, we inserted the BTKR enhancer or SV40 enhancer to augment the transcriptional activity (data not shown). Luciferase constructs containing −1.1 kb to +147 nt genomic DNA fragment and its truncated fragments with the BTKR enhancer were transfected into RAG-2-expressing lymphoid cell lines (LSB11-1, 18.8.1, or BAL17) and RAG-2-nonexpressing lymphoid cell lines (EL4 or NIH3T3), and relative luciferase activity was determined. As shown in Figure 2, a fragment containing −1.1 kb to +147 nt exhibited a significant promoter activity not only in RAG-2-expressing lymphoid cell lines but also in RAG-2-nonexpressing lymphoid cell lines. Successive deletion of 5' flanking region from −1.1 kb to −86 nt did not affect the promoter activity. A significant decrease in the RAG-2 promoter activity was seen when sequences between −86 and −41 nt were deleted. The promoter activity was completely lost by the deletion of sequences between −41 and −+44 nt.

To determine the cell specificity of the promoter region, luciferase constructs containing −639/+147 nt genomic DNA fragment and its truncated fragments with SV40 enhancer were transfected into a lymphoid cell line (18.8.1) and nonlymphoid cell lines (L and NIH3T3), and the relative promoter activity was assessed. As shown in Figure 3, the relative promoter activity was detected in the 18.8.1 cell line but not in either the L or NIH3T3 cell lines. The promoter activity was drastically reduced when DNA fragments were truncated from −86 to −41 nt in 18.8.1 cells. These results indicate the presence of the positive lymphoid-specific regulatory element(s) between the −86 and −44 nt region.

Mouse RAG-2 promoter binding protein expressed in B-cell lineage

Between −86 nt and +1 (a transcription initiation site), the −80/−17 nt region was well conserved between the mouse and human RAG-2 5' upstream region (Figure 1B), and this region exhibited the full promoter activity (data not shown). Thus, DNA binding proteins to the −80/−17 promoter region were searched by EMSA (Figure 4). By using the −80/−17 DNA fragment as a probe, only 2 major DNA/protein complexes were detected in the nuclear extract prepared from the 18.8.1 cells (Figure 4A, C1 and
C2 complexes). The unlabeled −80/−17 fragment completely inhibited the formation of the C1 and C2 complexes, which indicated that some nuclear proteins specifically bound to the fragment to form the C1 and C2 complexes. The C1 complex was detected not only in the nuclear extract of 18.8.1 pre–B cells but also in the NIH3T3 or L fibroblast cells. In contrast, the C2 complex was detected only in the nuclear extract of the 18.8.1 cells (Figure 4A).

To determine the specificity of the expression of these DNA binding proteins, nuclear extracts from various cell lines were prepared and analyzed by EMSA. As shown in Table 1, the nuclear protein forming C2 complex was found in the extracts of all B-lineage cells but not in those of the other lineage cells including the T-lineage cells. The C1 complex was detected in extracts of all cell lines investigated (data not shown). We referred the protein forming C2 complex as the RAG-2 promoter binding protein (R2BP).

To determine the binding region of R2BP, a series of RAG-2 promoter deletions were prepared and used as competitors for EMSA (Figure 4B). DNA fragments of −80/−17, −65/−17, or −51/−17 interfered in the formation of the C2 complex, while DNA fragments lacking the −30 to −17 nt region (−80/−42, −80/−30, or −65/−30) could not inhibit the formation of the C2 complex, which shows that the −30 to −17 nt region was indispensable for the binding of R2BP. To identify the nucleotides responsible for the binding of R2BP, the −80/−17 DNA fragments with serial nucleotide alterations between −30 and −17 nt (M1, M2, M3, or M4) were generated, and their ability to inhibit the formation of the C2 complex in EMSA was investigated. As shown in Figure 4C, the wild type −80/−17 fragment and either the M1, M2, M3, or M4 fragment completely inhibited the C2 complex formation, whereas the M2 fragment failed to inhibit the C2 complex formation. The results clearly show that the altered nucleotides in the M2 fragment are critical for the binding of R2BP.

Figure 5A shows the putative transcription factors that bind between the −40 and −17 nt region of the mouse RAG-2 promoter. To clarify which transcription factor(s) is responsible for the formation of the C2 complex, consensus binding sequences of c-Myb, Ikaros, and Pax-5 were generated, and their ability to inhibit the formation of the C2 complex was tested. As shown in Figure 5B, c-Myb binding and Ikaros binding sequences did not inhibit the binding of R2BP, whereas Pax-5 binding sequences completely inhibited the C2 complex formation. To determine which transcription factor(s) is responsible for the binding of R2BP, the −80/−17 DNA fragment, the mutant Pax-5 binding DNA sequence, to which Pax-5 cannot bind,27 did not inhibit the binding of R2BP. Furthermore, anti–Pax-5 antibody, but not anti–c-Myb antibody, caused a supershift of the C2 complex (Figure 5C). These results show that R2BP corresponds to Pax-5.

**Mouse RAG-2 promoter binding protein expressed in T-cell lineage**

Using the −80/−17 RAG-2 promoter fragment, we could not detect any DNA binding protein specifically expressed in the T-cell lineage. For putative binding sites of transcription factors revealed that a potential GATA binding sequence (CATC) exists in the −80/−66 sequence (Figure 6A), which is conserved between mice and humans (Figure 1B). Thus, we prepared a DNA fragment containing a tandem repeat of the GATA binding sequence (Figure 6, legend) and performed EMSA. As shown in Figure 6B, the C3 and C4 complexes were formed by proteins in the EL4 extract, and these complexes were inhibited by the GATA binding sequence as well as the −85/−56 sequence. Inhibition by the −85/−56 fragment was specific because the −51/−17 fragment did not inhibit the formation of the C3 and C4 complexes (data not shown).

At the top of the gel, a high molecular weight complex was observed, but the complex was not competed by the −85/−56

---

**Table 1. Expression of the mouse RAG-2 promoter binding protein specifically in B-lineage cells**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Lineage</th>
</tr>
</thead>
<tbody>
<tr>
<td>R2BP-expressing cell lines</td>
<td></td>
</tr>
<tr>
<td>18.8.1</td>
<td>pre-B</td>
</tr>
<tr>
<td>BAL17</td>
<td>B cell</td>
</tr>
<tr>
<td>WEHI231</td>
<td>B cell</td>
</tr>
<tr>
<td>WEHI279</td>
<td>B cell</td>
</tr>
<tr>
<td>R2BP-nonexpressing cell lines</td>
<td></td>
</tr>
<tr>
<td>LSB11-1</td>
<td>T cell</td>
</tr>
<tr>
<td>EL4</td>
<td>T cell</td>
</tr>
<tr>
<td>NIH3T3</td>
<td>fibroblast</td>
</tr>
<tr>
<td>L</td>
<td>fibroblast</td>
</tr>
<tr>
<td>M1</td>
<td>myeloid cell</td>
</tr>
</tbody>
</table>

Using cell extracts prepared from the above cell lines, DNA binding proteins were examined by EMSA using the −80/−17 nt DNA fragment as a probe (as described in Figure 4 legend).
formed EMSA. Nuclear extracts containing recombinant GA TA-3 fragment, we used the supershift of the C3 and C4 complexes. anti–GA TA-3 antibody, but not anti–c-Myb antibody, caused the GA TA-3 bound to the RAG-2 promoter. As shown in Figure 6C, a T-cell–specific GA TA family, we examined whether or not correspond to one with a single GA TA protein. Because GA TA-3 is the mouse RAG-2 promoter. The C3 complex may correspond to possible GA TA binding site located at the downstream of the C2 complex. When EMSA was performed using the DNA fragment containing the tandem repeat of the GATA binding sequence and the nuclear extracts containing recombinant GATA-3, the signal of the GATA-3 complex was more than 100-fold stronger than that formed with the −85/−56 fragment. Furthermore, when EMSA fragment, indicating that the DNA binding protein(s) forming this complex does not bind to the −85/−56 promoter region. The −85/−56 fragment with a mutation for the putative GATA binding sequence (Figure 6A) did not inhibit the C3 and C4 complex formation. The C3 and C4 complexes were detected in the nuclear extracts from other T cell lines, but they were not detected in those from B cell lines or nonlymphoid cell lines (Table 2). These results indicate that a GATA binding protein may be responsible for the C2 complex in the absence of the competitor is denoted as 100%. The effect of anti–Pax-5 antibody on EMSA. EMSA was performed as described above in the absence or the presence of anti–Pax-5 or anti–c-Myb antibody. The asterisk denotes the band shifted with the anti–Pax-5 antibody.

To further confirm the binding of GATA-3 to the −85/−56 fragment, we used the −85/−56 fragment as a probe and performed EMSA. Nuclear extracts containing recombinant GATA-3 were prepared from 293T cell transfectants and used for EMSA. As shown in Figure 6D, 2 protein/DNA complexes, C5 and C6, were formed, and the formation of these complexes was inhibited by the unlabeled −85/−56 fragment. In those complexes, only the C5 complex was specifically competed out by the consensus GATA binding sequence and supershifted by the binding of the anti–GATA-3 antibody. These results confirmed that GATA-3 binds to the −85/−56 mouse RAG-2 promoter fragment and forms the C5 complex. When EMSA was performed using the DNA fragment containing the tandem repeat of the GATA binding sequence and the nuclear extracts containing recombinant GATA-3, the signal of the GATA-3 complex was more than 100-fold stronger than that formed with the −85/−56 fragment. Furthermore, when EMSA were performed as described above in the presence of anti–GATA-3 or anti–c-Myb antibody. The asterisk denotes the band shifted with the anti–GATA-3 antibody.
Table 2. Expression of the DNA binding protein forming the C3 and C4 complexes

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Lineage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-C3/C4-expressing cell lines</td>
<td>T cell</td>
</tr>
<tr>
<td>EL4</td>
<td>T cell</td>
</tr>
<tr>
<td>NIH3T3</td>
<td>B cell</td>
</tr>
<tr>
<td>NIH3T3</td>
<td>fibroblast</td>
</tr>
<tr>
<td>WEHI3</td>
<td>myeloid cell</td>
</tr>
<tr>
<td>NF-C3/C4-nonexpressing cell lines</td>
<td>pre-B cell</td>
</tr>
<tr>
<td>18.8.1</td>
<td>18.8.1</td>
</tr>
<tr>
<td>WEHI231</td>
<td>L</td>
</tr>
<tr>
<td>NIH3T3</td>
<td>NIH3T3</td>
</tr>
<tr>
<td>WEHI3</td>
<td>WEHI3</td>
</tr>
</tbody>
</table>

Using cell extracts prepared from the above cell lines, DNA binding proteins were examined by EMSA (as described in Figure 6 legend).

Possible involvement of Pax-5 or GATA-3 in RAG-2 promoter activity in B or T cells

To examine whether Pax-5 or GATA-3 is involved in mouse RAG-2 promoter activity, luciferase constructs with the −86/+147 mouse RAG-2 promoter fragment containing the mutation for a Pax-5 binding site (M2) (Figure 4C) or for a GATA binding site (Gm) (Figure 6A) were transfected into a pre-B cell line, 18.8.1 cells, or an immature T cell line, LSB11-1, and the relative luciferase activity was measured. As shown in Figure 7, the M2 binding site exhibited a decreased promoter activity in the 18.8.1 cells but not in the LSB11-1 cells. Contrary to this, the Gm showed significantly decreased promoter activity in the LSB-11 cells but not in the 18.8.1 cells. The result suggests that Pax-5 is involved in activation of the RAG-2 promoter in B-lineage cells, and GATA-3 is involved in the activation of the RAG-2 promoter in T-lineage cells.

Discussion

To understand the regulatory mechanism of the RAG gene expression, we cloned the mouse RAG-2 genomic genes, determined its transcription initiation site as well as the core promoter region, and demonstrated the involvement of separate transcription factors in the regulation of RAG-2 promoter activity in B- and T-lineage cells. The transcription initiation site of mouse RAG-2, approximately 30 bp upstream from that of human RAG-2, was determined by 5′ RACE (Figure 1). We found that the 5′ flanking regions of both mouse and human RAG-2 were highly conserved, indicating that the fundamental transcriptional regulation of RAG-2 may be conserved between mice and humans. As demonstrated in the 5′ flanking region of human RAG-1 and RAG-2, no canonical TATA box is located within anticipated distances from the transcription initiation site of mouse RAG-2. However, a sequence (CTCAGTGG) similar to an initiator sequence (consensus, CTCANNTCT) was found at the major transcription initiation site. An initiator-like sequence (CTCTCCTT) is also located at the transcription initiation site of human RAG-2, as described by Zarrin et al. An initiator sequence directs the initiation site of transcription in some TATA-less promoter, such as the terminal deoxynucleotidyltransferase gene, and may play a role in localizing the transcriptional machinery to the RAG-2 promoter.

The 5′ flanking region of the mouse RAG-2 conferred a significant level of luciferase activity when transfected into RAG-2-expressing as well as RAG-2–nonexpressing lymphoid cell lines (Figure 2). However, its promoter region did not exhibit the luciferase activity when transfected into nonlymphoid cell lines (Figure 3). This clearly indicates that the minimal promoter region of the mouse RAG-2 contains a cis-element that confers lymphoid-specific expression of RAG-2. It also indicates that the differentiation stage-specific expression of RAG-2 may be regulated by other mechanisms such as the enhancer or suppressor cis-element or alteration of the chromatin structure. Concerning the chromatin structure, we and Fuller et al. demonstrated the appearance of DNase I hypersensitive sites surrounding mouse or human RAG-1, which is located adjacent to RAG-2 and expressed in concert with RAG-2, and that their appearance accompanies lymphocyte development and RAG-1 expression.

To search the transcriptional factors regulating the lymphoid-specific RAG-2 promoter activity, EMSA was performed with the core RAG-2 promoter fragment. We demonstrated that Pax-5 binds to the core promoter region in B-lineage cells and that GATA-3 binds to the region in the T-lineage cells (Figures 4-6). So far, there has been no identification of common lymphoid-specific factors that bind to the core RAG-2 promoter region. Furthermore, the alteration of nucleotides that abolished the binding of Pax-5 resulted in a decrease of the promoter activity in a B cell line but not in a T cell line. In contrast, the change of nucleotides that abolished the binding of GATA-3 exhibited a decrease of the promoter activity in a T cell line but not in a B cell line (Figure 7). The results indicate that these sites are important for the RAG-2 promoter activity when analyzed by luciferase reporter gene assay. It should be necessary to demonstrate the binding of Pax-5 or GATA-3 to these sites in situ in order to prove the physiological importance of these transcription factors in RAG-2 promoter activity.

It is noted that mutations in both Pax-5 binding and GATA-3 binding sites did not reduce the promoter activity to the background level, which indicates that other factor(s) may also be involved in the RAG-2 promoter activity. It is also noted that alteration of the Pax-5 binding site of the promoter region caused a significant enhancement of the promoter activity in a T cell line (Figure 7B). The data pose a possibility that repressing factor(s) bind to the promoter region.
Pax-5 binding site in T-lineage cells. In this respect, Figure 4 indicates the presence of an additional factor(s) other than Pax-5 or GATA-3 that binds to the −80/−17 mouse RAG-2 promoter region. The DNA binding protein forming the C1 complex existed in the extracts prepared from all cell lineages, and the complex formation was inhibited by the fragments −65/−17 and −51/−17, which demonstrates that the protein binding site may overlap with that of Pax-5. The database search revealed putative transcription factor binding sites in the −51/−17 fragment including the binding sites for CF-1, which interact with the c-myc and actin promoter as well as the immunoglobulin enhancer30; CREB, a cyclic adenosine monophosphate CcAMP response element binding protein31; and AP-1, a fos/jun complex.32 These factors are ubiquitously expressed and could repress the mouse RAG-2 promoter activity in T cells. This is merely a speculation and should be investigated at the molecular level.

Pax-5 is specifically expressed in B cells in lymphoid organs.33 It has been shown that B-cell differentiation was completely blocked at an early precursor stage in mice lacking Pax-5, although T-cell differentiation was not affected.34 On the contrary, GATA-3 was specifically expressed in T-lineage cells,35 and GATA-3+/− ES cells failed to differentiate into T-lineage cells.36 Recently it has also been indicated that GATA-3 is involved in Th2 cell development from the Th0 precursor cells.37 In this study we showed that these key transcription factors, which are involved in the commitment of either B or T lineage, play an important role in the promoter activity of mouse RAG-2. Concerning transcription factors regulating lymphocyte development, PU.1 and Ikaros are expressed in pluripotent stem cells, lymphoid progenitors, and immature or mature lymphocytes.38 During the commitment to lymphocytes, E2A, early B cell factor (EBF), and Pax-5 are expressed in B-lineage cells, and GATA-3 is expressed in T-lineage cells, which indicates that commitment to lymphocytes is regulated by different factors rather than common factors in B- and T-lineage cells.

Recently, Nutt et al39 showed that Pax-5−deficient pro-B cells, which had been expanded on stroma cells in the presence of interleukin-7 (IL-7), expressed RAG-1 and RAG-2, and the data indicated that Pax-5 is not necessarily required for RAG expression. However, it should be noted that the data also demonstrated that B-lymphoid progenitor cells could never be detected in Pax-5−deficient fetal liver, which strongly suggests that the function of Pax-5 can be compensated for by the other factors derived from stroma cells and/or IL-7. As described above, E2A and EBF are potential transcription factors during early B-cell development. However, no putative binding sites for these factors were present up to 86 nt in the mouse RAG-2 promoter region. It should be clarified whether such B-cell–specific transcription factors bind to a cis-element in the other region to regulate RAG-2 expression or whether other novel transcription factors are induced by signals from bone marrow stroma cells and IL-7.

During the preparation of our manuscript, a report40 indicating the involvement of Pax-5 in the regulation of the RAG-2 promoter in B cells was published. Lauring and Schlissel40 have characterized the promoter of the mouse RAG-2 gene and determined the transcription initiation site. When compared to the data in the present study, the transcription start site they determined was 29 nt downstream. They have also shown that deletion of the RAG-2 promoter region to −42 nt still possesses a full promoter activity in B-lineage cells. The authors concluded that the 3′ downstream region from the −42 nt was essential for the promoter activity in B-lineage cells. However, in this study we demonstrated that deletion of the RAG-2 promoter sequences to −86 nt showed a full promoter activity, but its deletion to −41 nt resulted in a decrease, by half, of the promoter activity in B-lineage cells (Figure 2). This indicates that the −86/−42 fragment is also involved in the RAG-2 promoter activity in B-lineage cells. In the case of T-lineage cells, they indicated that the −127/−78 region was indispensable for the promoter activity. However, we have shown here that the deletion to −86 nt still exhibited the full promoter activity in T-lineage cells, and we finally found that GATA-3 was bound to the −80/−56 region with a core sequence of 5′-ATC-3′ at −68 nt. Our data show that the −80/−42 region plays an important role in T-cell–specific regulation of the RAG-2 promoter activity. These contradictions between our data and theirs may be derived from the differences of reporter genes used. With this regard, we used luciferase reporter constructs with βTCR enhancer to augment the transcriptional promoter activity of RAG-2 in this study.

Analysis of the mouse RAG-2 promoter has provided insight into the basis of constitutive expression of RAG-2 in lymphocytes. Our study shows that the 5′ flanking region of mouse RAG-2 contains the promoter that confers lymphocyte-specific expression of RAG-2 and that distinct DNA binding proteins may separately regulate RAG-2 expression in B- and T-lineage cells. Lauring and Schlissel40 have demonstrated that Pax-5 binds to the RAG-2 promoter in vivo by in vivo footprint analysis. To demonstrate the role of GATA-3 in RAG-2 promoter activity in vivo, we should further analyze the binding of GATA-3 to the promoter region in T cells by in vivo footprint analysis as well as the effect of dominant negative GATA-3 on RAG-2 expression in T cells. It should also be noted that factors which confer the regulatory mechanisms for transcriptional activation as well as inactivation of the RAG-2 gene during lymphocyte development remain to be clarified.

Acknowledgments

We thank Dr K. Sakaguchi for providing 18.8.1, WEHI279, and BAL17 cell lines; Dr H. Kikutani for donating M1 and WEHI3 cell lines; and Dr M. Yamamoto for the generous gift of GATA-3 cDNA.

References


